Calprotectin I Serum as a Diagnostic Marker

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

113 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-03

Study Completion Date

2018-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Markers of COPD Exacerbations

NCT05315674

COPD COPD Exacerbation

RECRUITING

Low-dose CT for Diagnosis of Pneumonia in COPD Exacerbations and Comparison of the Inflammatory Profile.

NCT02264483

COPD Exacerbation

UNKNOWN

A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects

NCT00848406

Asthma Copd

COMPLETED

COPD Exacerbation Blood and Urine Biomarkers Study

NCT03823443

Chronic Obstructive Pulmonary Disease Acute Exacerbation Copd Alpha-1 Anti-trypsin Deficiency

TERMINATED

Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT03923803

Chronic Obstructive Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

np-AECOPD

Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission

No interventions assigned to this group

p-AECOPD

Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinically confirmed acute exacerbation of chronic obstructive pulmonary disorder (AECOPD)
* COPD diagnosis previously confirmed by spirometry according to the GOLD criteria.

Exclusion Criteria

* known malignant disease
* bronchiectasis
* chronic bacterial colonisation of the airways
* treatment with an immunosuppressive drug or long-term treatment with antibiotics.
* not examined with a chest X-ray at admission

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No